Gilead Sciences Increases Stake to 25.1% with $12.5M Purchase in Public Offering
ASMB has more than doubled off its 52-week low of $13.7.
Summary
Gilead Sciences, a strategic investor, increased its stake in Assembly Biosciences to 25.1% by investing $12.5 million in the company's recent public offering, signaling strong confidence.
Key Events · Ownership and Investor Activity · ASMB
-
Strategic Investor Increases Stake
Gilead Sciences, Inc. increased its beneficial ownership in Assembly Biosciences to 25.1% of outstanding common stock.
-
$12.5 Million Investment
Gilead purchased 471,698 shares for approximately $12.5 million in Assembly Biosciences' recent public offering on May 26, 2026.
-
Participation in Public Offering
This purchase was part of the public offering that closed on May 26, 2026, which raised approximately $115 million for Assembly Biosciences.
Analysis · ASMB · Life Sciences
Gilead Sciences, a major strategic investor, significantly increased its ownership in Assembly Biosciences by purchasing $12.5 million worth of common stock in the company's recent public offering. This substantial investment, representing nearly 3% of Assembly's market cap, demonstrates strong confidence from a key partner, especially as it helps absorb dilution from the offering.
At the time of this filing, ASMB was trading at $27.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $435.5M. The 52-week trading range was $13.70 to $39.71. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.